These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28619845)

  • 1. The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells through the upregulation of NOXA and synergizes with ibrutinib, 5-aminoimidazole-4-carboxamide riboside or venetoclax.
    Cosialls AM; Pomares H; Iglesias-Serret D; Saura-Esteller J; Núñez-Vázquez S; González-Gironès DM; de la Banda E; Preciado S; Albericio F; Lavilla R; Pons G; González-Barca EM; Gil J
    Haematologica; 2017 Sep; 102(9):1587-1593. PubMed ID: 28619845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NOXA upregulation by the prohibitin-binding compound fluorizoline is transcriptionally regulated by integrated stress response-induced ATF3 and ATF4.
    Núñez-Vázquez S; Sánchez-Vera I; Saura-Esteller J; Cosialls AM; Noisier AFM; Albericio F; Lavilla R; Pons G; Iglesias-Serret D; Gil J
    FEBS J; 2021 Feb; 288(4):1271-1285. PubMed ID: 32648994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
    Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
    Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells.
    Santidrián AF; González-Gironès DM; Iglesias-Serret D; Coll-Mulet L; Cosialls AM; de Frias M; Campàs C; González-Barca E; Alonso E; Labi V; Viollet B; Benito A; Pons G; Villunger A; Gil J
    Blood; 2010 Oct; 116(16):3023-32. PubMed ID: 20664053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting prohibitins induces apoptosis in acute myeloid leukemia cells.
    Pomares H; Palmeri CM; Iglesias-Serret D; Moncunill-Massaguer C; Saura-Esteller J; Núñez-Vázquez S; Gamundi E; Arnan M; Preciado S; Albericio F; Lavilla R; Pons G; González-Barca EM; Cosialls AM; Gil J
    Oncotarget; 2016 Oct; 7(40):64987-65000. PubMed ID: 27542247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The BCL-2 family members NOXA and BIM mediate fluorizoline-induced apoptosis in multiple myeloma cells.
    Cosialls AM; Sánchez-Vera I; Pomares H; Perramon-Andújar J; Sanchez-Esteban S; Palmeri CM; Iglesias-Serret D; Saura-Esteller J; Núñez-Vázquez S; Lavilla R; González-Barca EM; Pons G; Gil J
    Biochem Pharmacol; 2020 Oct; 180():114198. PubMed ID: 32798467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel prohibitin-binding compound induces the mitochondrial apoptotic pathway through NOXA and BIM upregulation.
    Moncunill-Massaguer C; Saura-Esteller J; Pérez-Perarnau A; Palmeri CM; Núñez-Vázquez S; Cosialls AM; González-Gironès DM; Pomares H; Korwitz A; Preciado S; Albericio F; Lavilla R; Pons G; Langer T; Iglesias-Serret D; Gil J
    Oncotarget; 2015 Dec; 6(39):41750-65. PubMed ID: 26497683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Waldenstrom macroglobulinemia cells devoid of BTK
    Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
    Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic leukemia cells
    Wierz M; Pierson S; Chouha N; Désaubry L; François JH; Berchem G; Paggetti J; Moussay E
    Haematologica; 2018 Apr; 103(4):e154-e157. PubMed ID: 29305413
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
    Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
    Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorizoline-induced apoptosis requires prohibitins in nematodes and human cells.
    Saura-Esteller J; Sánchez-Vera I; Núñez-Vázquez S; Jabalquinto-Carrasco J; Cosialls AM; Mendive-Tapia L; Kukhtar D; Martínez-Bueno MD; Lavilla R; Cerón J; Artal-Sanz M; Pons G; Iglesias-Serret D; Gil J
    Apoptosis; 2021 Feb; 26(1-2):83-95. PubMed ID: 33387147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unravelling the suboptimal response of TP53-mutated chronic lymphocytic leukaemia to ibrutinib.
    Guarini A; Peragine N; Messina M; Marinelli M; Ilari C; Cafforio L; Raponi S; Bonina S; Mariglia P; Mauro FR; Gaidano G; Del Giudice I; Foà R
    Br J Haematol; 2019 Feb; 184(3):392-396. PubMed ID: 30338509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2-Phenylacetylenesulfonamide (PAS) induces p53-independent apoptotic killing of B-chronic lymphocytic leukemia (CLL) cells.
    Steele AJ; Prentice AG; Hoffbrand AV; Yogashangary BC; Hart SM; Lowdell MW; Samuel ER; North JM; Nacheva EP; Chanalaris A; Kottaridis P; Cwynarski K; Wickremasinghe RG
    Blood; 2009 Aug; 114(6):1217-25. PubMed ID: 19515722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Creating novel translation inhibitors to target pro-survival proteins in chronic lymphocytic leukemia.
    Chen R; Zhu M; Chaudhari RR; Robles O; Chen Y; Skillern W; Qin Q; Wierda WG; Zhang S; Hull KG; Romo D; Plunkett W
    Leukemia; 2019 Jul; 33(7):1663-1674. PubMed ID: 30700841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.
    Oppermann S; Ylanko J; Shi Y; Hariharan S; Oakes CC; Brauer PM; Zúñiga-Pflücker JC; Leber B; Spaner DE; Andrews DW
    Blood; 2016 Aug; 128(7):934-47. PubMed ID: 27297795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential mechanisms of resistance to venetoclax and strategies to circumvent it.
    Tahir SK; Smith ML; Hessler P; Rapp LR; Idler KB; Park CH; Leverson JD; Lam LT
    BMC Cancer; 2017 Jun; 17(1):399. PubMed ID: 28578655
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of EZH2 and immune signaling exerts synergistic antitumor effects in chronic lymphocytic leukemia.
    Chartomatsidou E; Ntoufa S; Kotta K; Rovida A; Akritidou MA; Belloni D; Ferrero E; Trangas T; Stavroyianni N; Anagnostopoulos A; Rosenquist R; Ghia P; Papakonstantinou N; Stamatopoulos K
    Blood Adv; 2019 Jun; 3(12):1891-1896. PubMed ID: 31227476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Ibr-7 derivative of ibrutinib exhibits enhanced cytotoxicity against non-small cell lung cancer cells via targeting of mTORC1/S6 signaling.
    Zhang B; Wang L; Zhang Q; Yan Y; Jiang H; Hu R; Zhou X; Liu X; Feng J; Lin N
    Mol Oncol; 2019 Apr; 13(4):946-958. PubMed ID: 30663221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.